ABVC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
—
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
—
0
Operating Expenses
1.2M
+59.1%
779.5K
-50.4%
1.6M
—
2.0M
R&D
18.0K
-20.6%
22.7K
-31.4%
33.1K
—
29.9K
SG&A
1.2M
+61.5%
756.8K
+0.6%
752.0K
—
1.9M
Operating Income
-1240593
-59.1%
-779526
+50.4%
-1572472
—
-1964360
EBITDA
-1233687
-59.6%
-773010
+50.7%
-1566689
-27153.9%
5.8K
+100.3%
-1958539
Net Income
-1390132
-71.5%
-810481
+52.0%
-1689937
—
-2083473
EPS (Basic)
$0.04
+233.3%
$-0.03
+50.0%
$-0.06
—
$-0.09
EPS (Diluted)
$0.04
+233.3%
$-0.03
+50.0%
$-0.06
—
$-0.09
Shares (Diluted)
26.7M
+2.3%
26.1M
+2.4%
25.4M
+2.5%
24.8M
+6.7%
23.3M
ABVC BioPharma (ABVC) — Financials